Editas Medicine, Inc. (EDIT)

NASDAQ Healthcare Biotechnology

Editas Medicine, Inc. is a leading biotechnology firm focused on clinical-stage genome editing, with a primary mission to pioneer groundbreaking genetic therapies designed to address a wide array of severe medical conditions. The company leverages a unique, in-house developed gene editing platform that utilizes cutting-edge CRISPR technology. Editas's pipeline features several promising candidates, including EDIT-101, which is currently undergoing Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a genetic disorder causing inherited childhood blindness. Additionally, EDIT-102 is und…